Wedbush Securities Sees Dose Escalation Trials Continue Without Toxicity Signals For Endocyte

In a report published Tuesday, Wedbush Securities analyst David M. Nierengarten reiterated an Outperform rating and $12.00 price target on Endocyte, Inc. ECYT. In the report, Wedbush Securities noted, "ECYT reported a Q4:14 EPS of $(0.19), in line with our $(0.20) estimate and above consensus of ($0.25). As expected, cash burn was low, with ECYT ending the quarter well capitalized with $207M in cash and cash equivalents. Management guided to a YE:15 cash balance of $155M." Endocyte closed on Monday at $6.05.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorReiterationAnalyst RatingsDavid M. NierengartenWedbush Securities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!